450 related articles for article (PubMed ID: 24297090)
1. Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
van Genugten RE; van Raalte DH; Muskiet MH; Heymans MW; Pouwels PJ; Ouwens DM; Mari A; Diamant M
Eur J Endocrinol; 2014 Mar; 170(3):429-39. PubMed ID: 24297090
[TBL] [Abstract][Full Text] [Related]
2. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
3. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
4. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
[TBL] [Abstract][Full Text] [Related]
5. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
Alba M; Ahrén B; Inzucchi SE; Guan Y; Mallick M; Xu L; O'Neill EA; Williams-Herman DE; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2013 Dec; 15(12):1101-10. PubMed ID: 23782502
[TBL] [Abstract][Full Text] [Related]
6. Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance?
van Raalte DH; Kwa KA; van Genugten RE; Tushuizen ME; Holst JJ; Deacon CF; Karemaker JM; Heine RJ; Mari A; Diamant M
Metabolism; 2013 Apr; 62(4):568-77. PubMed ID: 23164480
[TBL] [Abstract][Full Text] [Related]
7. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.
Bock G; Dalla Man C; Micheletto F; Basu R; Giesler PD; Laugen J; Deacon CF; Holst JJ; Toffolo G; Cobelli C; Rizza RA; Vella A
Clin Endocrinol (Oxf); 2010 Aug; 73(2):189-96. PubMed ID: 20039889
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.
Muscelli E; Casolaro A; Gastaldelli A; Mari A; Seghieri G; Astiarraga B; Chen Y; Alba M; Holst J; Ferrannini E
J Clin Endocrinol Metab; 2012 Aug; 97(8):2818-26. PubMed ID: 22685234
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
10. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
11. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans.
van Raalte DH; van Genugten RE; Linssen MM; Ouwens DM; Diamant M
Diabetes Care; 2011 Feb; 34(2):412-7. PubMed ID: 21216851
[TBL] [Abstract][Full Text] [Related]
13. Effect of Sitagliptin on Islet Function in Pancreatic Insufficient Cystic Fibrosis With Abnormal Glucose Tolerance.
Kelly A; Sheikh S; Stefanovski D; Peleckis AJ; Nyirjesy SC; Eiel JN; Sidhaye A; Localio R; Gallop R; De Leon DD; Hadjiliadis D; Rubenstein RC; Rickels MR
J Clin Endocrinol Metab; 2021 Aug; 106(9):2617-2634. PubMed ID: 34406395
[TBL] [Abstract][Full Text] [Related]
14. Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men.
van Raalte DH; Nofrate V; Bunck MC; van Iersel T; Elassaiss Schaap J; Nässander UK; Heine RJ; Mari A; Dokter WH; Diamant M
Eur J Endocrinol; 2010 Apr; 162(4):729-35. PubMed ID: 20124412
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
16. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Azuma K; Rádiková Z; Mancino J; Toledo FG; Thomas E; Kangani C; Dalla Man C; Cobelli C; Holst JJ; Deacon CF; He Y; Ligueros-Saylan M; Serra D; Foley JE; Kelley DE
J Clin Endocrinol Metab; 2008 Feb; 93(2):459-64. PubMed ID: 18042650
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
18. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
19. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
